AMRX — Q2 2026 Financial Report Analysis

Overview

Amneal grew second-quarter 2026 net revenue 10% to $796 million, with its generic-drug business (Affordable Medicines, +13%) and its branded drugs (Specialty, +17%) both growing faster than the company as a whole. Net income attributable to shareholders rose to $58 million from $22 million, but most of that jump in the bottom line came from an unusually low tax bill and lower amortization charges, not from the business suddenly getting far more profitable. The cleaner read is adjusted EBITDA (earnings before interest, tax, depreciation and amortization, excluding items management treats as non-recurring) up 12% to $206 million and adjusted EPS up 20% to $0.30. Management raised full-year guidance for the second time this year. The figures here come from the 10-Q for the quarter ended June 30, 2026, filed August 6, and the July 30 earnings release.

At a glance

• Revenue +9.9% to $796.2 million: new generic launches added $44.8 million of year-over-year growth on their own, and the CREXONT, BREKIYA and UNITHROID brands added another $29 million.
• GAAP diluted EPS $0.18 vs $0.07: pre-tax income rose 37%, but the effective tax rate fell to 1.9% from 31.1%, which by our estimate accounts for roughly $0.06 of the $0.11 increase.
• Operating cash flow was −$48 million in the first half against $148 million of net income: receivables and inventory each absorbed about $125 million, and opioid-settlement and tax-receivable-agreement payments took another $75 million.

The numbers

Segment performance

Amneal reports three segments: Affordable Medicines (generic drugs, injectables and biosimilars — cheaper copies of drugs whose patents have expired), Specialty (its own branded drugs, mainly for Parkinson's disease, migraine and thyroid conditions) and AvKARE (a distributor that sells mostly to US government buyers such as the Veterans Administration).

Affordable Medicines. The 10-Q attributes the $56.5 million revenue increase mainly to products launched in 2025 and 2026 ($44.8 million of growth) plus higher sales of women's health medicines "due to market conditions," partly offset by price erosion — the steady price declines that come with being one of several makers of the same generic. Gross margin edged up to 42.3% from 41.7% on a better mix of newer products, despite higher plant and freight costs and more inventory written off as obsolete. Segment selling, general and administrative (SG&A) costs rose 23.8%, while R&D fell 21.2% on lower in-licensing and milestone payments. In April Amneal also paid $75.0 million upfront for exclusive US distribution of generic mirabegron (a copy of the bladder drug Myrbetriq), which it is amortizing over five years.

Specialty. CREXONT (a Parkinson's drug launched in 2024) added $17.6 million of year-over-year sales, UNITHROID (thyroid) $5.9 million and the BREKIYA migraine autoinjector $5.5 million, more than offsetting the "expected decline" of RYTARY, the older Parkinson's drug CREXONT is meant to replace. The 54.6% jump in operating income looks dramatic but is mostly accounting: amortization charged to cost of goods fell by $14.1 million (some acquired product rights are reaching the end of their amortization schedule), lifting GAAP gross margin to 67.7% from 56.4%. Excluding amortization, Specialty gross margin actually slipped to 80.3% from 82.1%, and SG&A rose 32.3% on launch spending for CREXONT and BREKIYA. Adjusted segment operating income grew 6.4% ($74.5 million vs $70.0 million) — that is the underlying pace.

AvKARE. Revenue fell 3.7% as Amneal deliberately shrank a low-margin distribution channel, partly offset by growth in its government channel. Gross margin dropped to 16.7% from 20.4% largely because of a $5.6 million increase in inventory obsolescence, and operating income nearly halved.

What the headline numbers hide

• Taxes did much of the heavy lifting on GAAP earnings. Pre-tax income rose 37% ($71.0 million vs $51.7 million), but the tax provision fell to $1.4 million from $16.1 million. The 10-Q attributes the change to the mix of income across jurisdictions, the One Big Beautiful Bill Act enacted in July 2025, and discrete share-based-compensation items. Had the quarter been taxed at last year's 31.1% rate, our calculation puts diluted EPS near $0.11 rather than $0.18. Adjusted EPS applies a normalized ~25% tax rate in both years, which is why its 20% growth is the more reliable gauge.
• Lower amortization flatters margins. Total amortization fell to $34.0 million from $44.8 million. Amortization is a non-cash charge that spreads the cost of acquired product rights over time, so its decline lifts GAAP gross margin without any change in how profitably drugs are being made or sold.
• Below the operating line, it was a wash. Interest expense fell $10.1 million on lower rates on variable-rate debt, but a $2.0 million foreign-exchange loss replaced an $8.3 million gain a year ago, so total other expense was almost unchanged ($58.8 million vs $59.7 million).
• Cash conversion is poor so far this year. First-half operating cash flow was −$48.0 million versus +$91.2 million a year earlier, while net income was $147.6 million. The 10-Q points to $35.9 million of opioid-settlement payments, $38.8 million paid under the tax receivable agreement, slower receivable collections "due to timing," and inventory built up for growth initiatives. Trade receivables rose 14.0% in six months to $1.02 billion and inventory 11.8% to $678 million, both faster than first-half revenue growth of 7.0%. Full-year guidance still calls for $350–400 million of operating cash flow, which implies roughly $400–450 million in the second half — a large swing that depends on those receivables actually being collected.
• GAAP vs adjusted gap. Adjusted net income of $98.7 million versus GAAP net income of $69.6 million (before non-controlling interests) excludes $34.0 million of amortization, $10.4 million of stock-based compensation, $8.1 million of acquisition and site costs (mostly the Kashiv deal), $9.1 million of legal charges (mainly antitrust class actions), $6.9 million of non-cash interest and a $2.4 million tax-receivable-agreement charge, then adds back tax at a normalized rate. Most of these are recurring in nature for an acquisitive drugmaker; stock compensation and amortization are real costs.
• Share count is about to step up. Diluted shares were up only 1.8% year over year, so buybacks played no part in EPS growth. But the Kashiv acquisition, which closed August 10, issued 28.9 million new shares — about 9% of the Q2 diluted count — and management's guidance assumes roughly 340 million diluted shares for 2026.

Takeaway: Amneal's operations improved at a healthy but unspectacular pace — adjusted EPS +20%, adjusted EBITDA +12% — while the 157% jump in GAAP earnings mostly reflects a 1.9% tax rate and lower amortization. The figure to watch is cash: first-half operating cash flow was negative, and debt is rising just as a large acquisition closes.

Debt and the Kashiv deal

Net debt (borrowings minus cash) rose to $2.66 billion at June 30 from $2.41 billion at year-end, as cash fell to $128 million and the company drew $100 million on its revolving credit line. Net leverage — net debt divided by the last twelve months' adjusted EBITDA of $743 million — ticked up to 3.6x from 3.5x.

After the quarter, Amneal completed its purchase of Kashiv BioSciences on August 10 for $375 million in cash (subject to adjustments) plus 28.9 million shares, with up to $350 million more in milestone payments tied to US approvals of six product candidates and a 12-year profit-linked royalty. Kashiv is partly owned by members of Amneal's founding group, which makes this a related-party deal and has already drawn two shareholder lawsuits. To fund it, Amneal added a $350 million term loan and drew $180 million more on its revolver in late July and early August. Separately, it repriced its $2.08 billion term loan to 2.50 percentage points over SOFR (the benchmark short-term rate) from 3.00, which it expects to save about $12 million a year in cash interest. Management's stated goal is net leverage below 3.0x by 2028.

Outlook

Management raised its 2026 guidance:

With first-half revenue of $1.52 billion and adjusted EPS of $0.57, the new range implies second-half revenue of about $1.58–1.68 billion and adjusted EPS of $0.39–0.49, on a share count that now includes the Kashiv shares. The revenue range was lifted more ($50 million at both ends) than adjusted EBITDA ($10 million) or EPS (a cent), which fits a year where launch spending and higher plant costs absorb part of the extra sales.

Our read: the generic business is growing on new launches rather than price, and the branded franchise is successfully moving patients from RYTARY to CREXONT, so revenue momentum looks credible. The weaker points are the balance sheet and cash flow — leverage is heading up, not down, after Kashiv, and the full-year cash-flow target depends on a sharp second-half reversal in working capital. The Q3 report should show whether receivables come down and how much Kashiv adds to costs before its biosimilars contribute meaningful revenue.